Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCAR-119 in CD19+ Leukemia and Lymphoma
NCT02892695Phase 2Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Sep 2016
- Primary completion
- Sep 2018
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PCAR-119 in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Follicular lymphoma (FL) and 3 more, sponsored by PersonGen BioTherapeutics. Primary endpoint: Adverse events attributed to the administration of the anti-CD19 CAR-NK cells at 2 years. Status: unknown.
02
Drugs
PCAR-119
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)Follicular lymphoma (FL)Mantle cell lymphoma (MCL)B-cell prolymphocytic leukemia (B-PLL)
Beyond the preview
Go deeper on NCT02892695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02892695.